459 related articles for article (PubMed ID: 30306859)
61. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
62. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
63. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
65. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
Page MM; Watts GF
Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
[TBL] [Abstract][Full Text] [Related]
66. Understanding PCSK9 and anti-PCSK9 therapies.
McKenney JM
J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
[TBL] [Abstract][Full Text] [Related]
67. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
68. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
69. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
Schreml J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
[TBL] [Abstract][Full Text] [Related]
70. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
Pandey P; Zhao C; Liu B
Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321
[TBL] [Abstract][Full Text] [Related]
71. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
72. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
Elbitar S; Khoury PE; Ghaleb Y; Rabès JP; Varret M; Seidah NG; Boileau C; Abifadel M
Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211
[TBL] [Abstract][Full Text] [Related]
73. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
Filippatos TD; Kei A; Rizos CV; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
[TBL] [Abstract][Full Text] [Related]
74. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
[TBL] [Abstract][Full Text] [Related]
75. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
76. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.
Orringer CE; Jacobson TA; Saseen JJ; Brown AS; Gotto AM; Ross JL; Underberg JA
J Clin Lipidol; 2017; 11(4):880-890. PubMed ID: 28532784
[TBL] [Abstract][Full Text] [Related]
77. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
78. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
79. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
Sible AM; Nawarskas JJ; Anderson JR
Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
[TBL] [Abstract][Full Text] [Related]
80. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
